Category - Markets

Maxim Group reduced its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $4 from $7, saying demand for the company’s keyhole limpet hemocyanin (KLH) is a slow climb. The stock was quoted at $2.59 at midday Dec...

Ladenburg Thalmann slashed its price target for Aradigm (NASDAQ:ARDM) to $7.50 from $26 but maintained its “buy” rating after the company reported mixed top-line Phase 3 results for Pulmaquin for the treatment of non...

Roth Capital Partners initiated coverage of Inotek Pharmaceuticals (NASDAQ:ITEK) with a “buy” rating and $10 price target. The stock closed at $6.40 on Nov. 30. “In our opinion, Inotek’s trabodenoson has the...

Ladenburg Thalmann initiated coverage of Bellicum Pharmaceuticals (NASDAQ:BLCM) with a “buy” rating and $31 price target. The stock closed at $19.16 on Nov. 29. Bellicum is developing novel cellular immunotherapies for...

William Blair downgraded Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “market perform” from “outperform” and slashed its price target to $2 from $12. The stock closed at $4.39 on Tuesday. After markets closed on Nov. 29...

Leerink initiated coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $54 price target. The stock closed at $28.04 on Monday. Analyst Seamus Fernandez writes that the company’s lead asset, A...

Stifel downgraded Nivalis Therapeutics (NASDAQ:NVLS) to “ hold” from “buy” and slashed its price target to $3.25 from $16 after the company released Phase 2 data for cavosonstat in the treatment of patients with...

Piper Jaffray initiated coverage of Bovie Medical (NYSE:BVX) with an “overweight” rating and $6 price target. The stock closed at $4.24 on Friday. Bovie is best known within the operating room for its electrocautery...

Mackie Research Capital raised its price target for Profound Medical (TSX-V:PRN) to $4.40 from $3.30 after the company reported third quarter results. The stock closed at $1 on Thursday. Analyst Andre Uddin writes that...

Ladenburg Thalmann upgraded Repros Therapeutics (NASDAQ:RPRX) to “buy” from “neutral,” with a new price target of $5.50. The stock closed at $1.93 on Wednesday. In a new report, analyst Matthew Kaplan writes that Repros...